Previous 10 | Next 10 |
Gainers: Clearside Biomedical CLSD +38%. Cellectis (NASDAQ:CLLS) +13%. NeuroPace (NASDAQ:NPCE) +12%. 4D pharma LBPS +11%. LifeStance Health (NASDAQ:LFST) +8%. Losers: Orphazyme ORPH -37%. Aesthetic Medical International (NASDAQ:AIH) -19%. Suns...
Clearside Biomedical (NASDAQ:CLSD) +30% on Q4 results. Pearson (NYSE:PSO) +21% on report Apollo considering making offer for education company. Lazydays Holdings (NASDAQ:LAZY) +19%. 4D pharma (NASDAQ:LBPS) +18%. Superior Drilling Products (NYSE:SDPI) +16% on Q4 r...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Off...
- IND clearance marks the expansion of 4D pharma’s clinical-stage pipeline of single strain Live Biotherapeutics into neurology - First US FDA IND clearance for a Live Biotherapeutic for Parkinson’s disease 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) ...
- Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference call and webcast to discuss res...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that it will host a virtual Key Opinion Leader (KOL) event to review previously discl...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, and Alex Stevenson, Chief S...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the appointment of John Doyle as Chief Financial Officer (CFO). Mr. Doyle brings over...
Part A of the study meets primary endpoint of safety and tolerability Achieved multiple key secondary endpoints relating to improved asthma control compared to placebo 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of L...
Results demonstrate changes in gut microbiome structure following administration of Blautix in both IBS-C and IBS-D patients 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of dr...
News, Short Squeeze, Breakout and More Instantly...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (ȁ...
4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company’s request for a...
- Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months - Study sites are open for patient enrolment 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LB...